factor XIII concentrate, human

Drug Overview

Factor XIII concentrate, human is a highly specialized, life-saving medication within the hematology category. It is specifically designed for patients living with one of the rarest bleeding disorders in the world. Classified as a Coagulation Factor XIII product, this powerful Biologic is extracted and highly purified from the plasma of healthy human blood donors. Unlike newer lab-made alternatives that only replace one part of the protein, this human-derived therapy delivers the complete, natural Factor XIII protein complex. It provides a highly effective and safe method to prevent spontaneous, life-threatening hemorrhages and protect patients from chronic joint damage.

• Generic Name / Active Ingredient: Factor XIII concentrate (Human)
• US Brand Names: Corifact (known as Fibrogammin in European and international markets)
• Drug Class: Coagulation Factor XIII / Plasma-Derived Antihemorrhagic
• Route of Administration: Intravenous (IV) injection
• FDA Approval Status: Fully FDA-approved for adults and children.
  
  Find facts on factor XIII concentrate, human. Discover its specific medical uses, health benefits, side effects, and precise dosage guides.

What Is It and How Does It Work? (Mechanism of Action)

To understand how this Biologic works, it helps to visualize the final steps of how the body stops bleeding. When a blood vessel tears, the body triggers a chain reaction that ultimately forms a web made of a protein called fibrin to plug the hole. However, a newly formed fibrin web is fragile and breaks apart easily. Factor XIII is the final enzyme in this chain reaction; it acts like the biological “glue” that cements the web together.

Natural human Factor XIII is composed of two distinct parts: the A-subunit (the active enzyme that does the gluing) and the B-subunit (a carrier protein that protects the A-subunit in the bloodstream). Patients with congenital Factor XIII deficiency have a genetic mutation that prevents them from making enough of these proteins. Because of this, their bodies can start to form a clot, but the clot breaks apart prematurely. This leads to delayed, severe bleeding that often starts 24 to 48 hours after a minor injury.

When a patient receives an intravenous infusion of human Factor XIII concentrate, they are receiving the complete, natural protein containing both the A and B subunits. Once the Biologic enters the bloodstream, it is activated by calcium and another enzyme called thrombin at the site of the injury. The activated Factor XIII creates strong chemical cross-links between the fibrin strands. This reinforces the clot, making it physically hard, durable, and resistant to premature breakdown, successfully stopping the hemorrhage.

FDA-Approved Clinical Indications

Primary Indication

The primary clinical indication for human Factor XIII concentrate is the routine prophylactic treatment and perioperative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency. Its main goal is to maintain a constant, safe level of Factor XIII in the patient’s blood. This routine prevention stops spontaneous joint bleeds, soft tissue hemorrhages, and life-threatening intracranial (brain) bleeding, which is a major risk for patients with this condition.

Other Approved & Off-Label Uses

• Acquired Factor XIII Deficiency (Off-Label): In rare cases, major surgeries, severe inflammatory bowel disease, or massive bleeding can cause a patient’s body to use up all its natural Factor XIII. Hematologists may use this product off-label to support these patients until their bodies can recover.
• Note: This medication is exclusively for Factor XIII deficiency and will not treat Hemophilia A, Hemophilia B, or von Willebrand disease.

Dosage and Administration Protocols

Because Factor XIII naturally stays in the bloodstream for a very long time, dosing for this medication is highly convenient compared to standard hemophilia treatments. It is calculated based on the patient’s body weight and is measured in International Units (IU).

Important Adjustments:

• Dose Titration: If a patient experiences breakthrough bleeding or if their blood tests show that the medication is clearing from their body too quickly, the hematologist may increase the dose or shorten the schedule to every 21 days.
• Infusion Rate: The medication should be administered at a slow, comfortable rate, typically not exceeding 4 mL per minute, to prevent sudden drops in blood pressure or allergic reactions.
• Hepatic and Renal Impairment: There are no mandatory mathematical dose reductions required purely for kidney or liver impairment, though close clinical monitoring is recommended.

Clinical Efficacy and Research Results

Clinical data from 2020 through 2026 continues to demonstrate the profound efficacy of this once-a-month Biologic. Because congenital Factor XIII deficiency carries a high risk of fatal brain bleeds in childhood, routine prophylaxis is critical. Global registries show that patients receiving routine monthly infusions of human Factor XIII concentrate achieve an Annualized Bleeding Rate (ABR) of nearly zero. The therapy reliably maintains Factor XIII trough levels well above the 5% to 10% threshold required to prevent spontaneous bleeding. This high level of protection allows patients to live active, normal lives while preventing the early-onset arthritis caused by repeated joint bleeds.

Safety Profile and Side Effects

Black Box Warning

Factor XIII concentrate, human does not carry an FDA Black Box Warning. It is recognized as a safe and highly effective therapy when used according to clinical guidelines.

Common side effects (>10%)

Because this medication is highly purified and matches the body’s natural proteins, it is generally very well tolerated. When side effects do occur, they are typically mild and may include:

• Joint pain (arthralgia)
• Headache
• Mild fever or chills shortly after the infusion
• Injection site reactions (mild pain or redness)

Serious adverse events

• Thromboembolic Events: Introducing concentrated clotting factors carries a theoretical risk of over-activating the coagulation cascade, which could lead to unwanted blood clots in the deep veins, lungs, or brain.
• Severe Hypersensitivity / Anaphylaxis: A life-threatening allergic reaction to the human plasma proteins contained in the Biologic.
• Inhibitor Development: The immune system may mistakenly recognize the infused proteins as a threat and create neutralizing antibodies (inhibitors). This destroys the medication’s effectiveness and causes bleeding to return.
• Infectious Agents: Because the drug is derived from human plasma, there is an incredibly small, theoretical risk of transmitting human viruses. Modern purification processes (including pasteurization and viral filtration) make this risk exceptionally low.

Management Strategies

If a patient develops chest tightness, severe wheezing, hives, or dizziness during an infusion, the therapy must be stopped instantly, and emergency medications (like epinephrine) must be administered. If unexpected bleeding occurs despite sticking to the monthly schedule, the healthcare provider must urgently perform blood tests to check for the presence of neutralizing inhibitors.

Research Areas

Because congenital Factor XIII deficiency is incredibly rare (affecting roughly 1 in 2 million people), international collaboration is required for research. Current hematology research focuses heavily on long-term safety and quality-of-life registries. Researchers are comparing the long-term outcomes of patients using human plasma-derived Factor XIII (which contains both A and B subunits) against those using the newer recombinant Factor XIII (which contains only the A subunit) to determine if one provides superior long-term joint protection.

Disclaimer: These studies regarding long-term comparative outcomes of plasma-derived and recombinant Factor XIII are still exploratory and are not yet applicable to practical or professional clinical scenarios. While both products are used for prophylaxis, claims of superior long-term joint protection, universal registry-based conclusions, or clear long-term outcome advantages remain insufficiently supported by evidence and should be interpreted cautiously.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Clot Solubility Test / FXIII Assay: Standard bleeding tests (like PT and aPTT) are completely normal in these patients. Specialized clot solubility tests or specific Factor XIII activity assays are required to confirm the diagnosis.
• Viral Screening: Baseline testing for Hepatitis A, B, C, and HIV is a standard, required safety protocol for any patient starting a human plasma-derived product.

Precautions during treatment

• Hepatitis Vaccination: All patients receiving plasma-derived products must be vaccinated against Hepatitis A and Hepatitis B to ensure maximum safety.
• Thrombosis Vigilance: Patients should be educated on the warning signs of blood clots, particularly if they have a history of heart disease, obesity, or are undergoing a surgery that requires prolonged bed rest.

“Do’s and Don’ts” List

• Do infuse your medication exactly on time, every 28 days, as prescribed by your hematology team.
• Do treat any suspected head trauma as a severe medical emergency, even if it seems minor, and go to the emergency room immediately.
• Do keep an accurate, detailed calendar of all your infusions and any unusual bruising, and share this with your doctor.
• Don’t use pain medications containing aspirin, ibuprofen, or naproxen (NSAIDs), as these interfere with your blood platelets and increase the risk of bleeding. Use acetaminophen instead.
• Don’t shake the vial vigorously when mixing the powder with the sterile water; gently swirl it to prevent destroying the fragile Biologic proteins.
• Don’t participate in high-impact contact sports without explicit clearance from your medical team and confirmation that your Factor XIII levels are protected.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. This content is not intended to substitute for professional medical diagnosis, treatment protocols, or clinical judgment. Always consult your hematologist, physician, or other qualified health provider with any questions you may have regarding a rare bleeding disorder or before making any changes to your prescribed treatment regimen.